Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVKW0N)

• Drug Name: Coumate Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 9859866
  CAS Number: CAS 136167-05-0
  TTD Drug ID: DMVKW0N

Molecule-Related Drug Atlas

Drug(s) Targeting Carbonic anhydrase VI (CA-VI)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[4]
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[5]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[6]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[7]
SAR566658	DM6Q295	Solid tumour/cancer	2A00-2F9Z	Phase 2	[8]
FERULIC ACID	DMJC7NF	Discovery agent	N.A.	Patented	[7]
SPERMINE	DMD4BFY	N. A.	N. A.	Terminated	[9]
ELLAGIC ACID	DMX8BS5	Discovery agent	N.A.	Investigative	[7]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[10]
CATECHIN	DMY38SB	Discovery agent	N.A.	Investigative	[6]

Drug(s) Targeting Carbonic anhydrase I (CA-I)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[4]
Ethoxzolamide	DMVO4ED	Glaucoma/ocular hypertension	9C61	Approved	[11]
Dichlorphenamide	DMH7IDQ	Chronic glaucoma	9C61.0Z	Approved	[11]
Methazolamide	DM7J2TA	Glaucoma/ocular hypertension	9C61	Approved	[12]
Acetazolamide	DM1AF5U	Absence epilepsy		Approved	[11]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[6]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[7]
CG-100649	DMIKMA9	Arthritis	FA20	Phase 3	[13]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[6]
SULFAMIDE	DMMAS3K	N. A.	N. A.	Phase 1	[14]

Drug(s) Targeting Aromatase (CYP19A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Anastrozole	DMNP60F	Breast cancer	2C60-2C65	Approved	[15]
Letrozole	DMH07Y3	Estrogen-receptor positive breast cancer		Approved	[16]
Exemestane	DM9HPW3	Hormonally-responsive breast cancer	2C60-2C65	Approved	[16]
Aminoglutethimide	DMWFHMZ	Cushing disease	5A70	Approved	[17]
FADROZOLE	DM3C5GZ	Breast cancer	2C60-2C65	Approved	[18]
Testolactone	DMVY4GN	Breast cancer	2C60-2C65	Approved	[19]
LIAROZOLE	DM4OYXE	Dermatological disease	DA24.Y	Phase 2/3	[20]
BGS-649	DMO4MNQ	Endometriosis	GA10	Phase 2	[21]
NARINGENIN	DMHAZLM	N. A.	N. A.	Phase 1	[20]
FORMESTANE	DMWIDJK	Breast cancer	2C60-2C65	Withdrawn from market	[22]

Drug(s) Targeting Carbonic anhydrase XII (CA-XII)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[4]
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[23]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[6]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[7]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[6]
FERULIC ACID	DMJC7NF	Discovery agent	N.A.	Patented	[7]
ELLAGIC ACID	DMX8BS5	Discovery agent	N.A.	Investigative	[7]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[10]
CATECHIN	DMY38SB	Discovery agent	N.A.	Investigative	[6]
GALLICACID	DM6Y3A0	Discovery agent	N.A.	Investigative	[7]

Drug(s) Targeting Carbonic anhydrase II (CA-II)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[4]
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[23]
Dorzolamide	DMA17D0	Ocular hypertension	9C61.01	Approved	[24]
Chlorothiazide	DMLHESP	Chronic heart failure	BD1Z	Approved	[25]
Ethoxzolamide	DMVO4ED	Glaucoma/ocular hypertension	9C61	Approved	[26]
Dichlorphenamide	DMH7IDQ	Chronic glaucoma	9C61.0Z	Approved	[26]
Cyclothiazide	DMJ4AWC	Congestive heart failure	BD10	Approved	[27]
Ethinamate	DMK57GB	Insomnia	7A00-7A0Z	Approved	[28]
Benzthiazide	DMQWZ0H	High blood pressure	BA00	Approved	[29]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[6]

Drug(s) Targeting Carbonic anhydrase XIV (CA-XIV)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[30]
TRIENTINE	DMD2WPG	Inborn error of metabolism	5C50-5C59	Approved	[9]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[6]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[7]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[6]
FERULIC ACID	DMJC7NF	Discovery agent	N.A.	Patented	[7]
SPERMINE	DMD4BFY	N. A.	N. A.	Terminated	[9]
ELLAGIC ACID	DMX8BS5	Discovery agent	N.A.	Investigative	[7]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[10]
CATECHIN	DMY38SB	Discovery agent	N.A.	Investigative	[6]

Drug(s) Targeting Steryl-sulfatase (STS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tranilast	DME5Y64	Allergic rhinitis	CA08.0	Approved	[31]
STX-140	DMJK5CT	Osteoporosis	FB83.0	Phase 2	[32]
PGL-2001	DMKA705	Endometriosis	GA10	Phase 2	[33]
PGL-2	DMJTYO4	Endometriosis	GA10	Phase 2	[33]
STX 64	DMJAPRK	Prostate cancer	2C82.0	Phase 1	[34]
B-Octylglucoside	DMMO75G	Discovery agent	N.A.	Investigative	[35]
EMATE	DMFQX1U	Discovery agent	N.A.	Investigative	[36]
Sulfamic acid 2-nonyl-4-oxo-4H-chromen-6-yl ester	DMM70K1	Discovery agent	N.A.	Investigative	[37]
Estradiol 17-O-sulfamate	DM7K14V	Discovery agent	N.A.	Investigative	[32]
4-Sulfamoyloxy-benzoic acid pentyl ester	DMZIFW7	Discovery agent	N.A.	Investigative	[38]

Drug(s) Targeting Carbonic anhydrase (CA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[39]
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[5]
Quinethazone	DMWCOSR	Hypertension	BA00-BA04	Approved	[40]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[6]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[7]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[6]
SULFAMIDE	DMMAS3K	N. A.	N. A.	Phase 1	[41]
FERULIC ACID	DMJC7NF	Discovery agent	N.A.	Patented	[7]
PMID30074415-Compound-21	DM3NPOU	N. A.	N. A.	Patented	[42]
Imatinib and nilotinib derivative 2	DM34NZ8	Cas mediated disorder	N.A.	Patented	[42]

Drug(s) Targeting Carbonic anhydrase IV (CA-IV)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[4]
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[43]
Brinzolamide	DMBAPFG	Ocular hypertension	9C61.01	Approved	[11]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[6]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[7]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[6]
Sodium pyruvate	DMST6A3	Asthma	CA23	Phase 1/2	[44]
SULFAMIDE	DMMAS3K	N. A.	N. A.	Phase 1	[41]
FERULIC ACID	DMJC7NF	Discovery agent	N.A.	Patented	[7]
SPERMINE	DMD4BFY	N. A.	N. A.	Terminated	[9]

Drug(s) Targeting Carbonic anhydrase IX (CA-IX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[6]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[7]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[6]
INDISULAM	DM9SX6Y	Lymphoma	2A80-2A86	Phase 2	[45]
Girentuximab I-124	DMG3O2Z	Renal cell carcinoma	2C90	Phase 2	[46]
SULFAMIDE	DMMAS3K	N. A.	N. A.	Phase 1	[47]
BAY 79-4620	DM14XQN	Solid tumour/cancer	2A00-2F9Z	Phase 1	[48]
90Y-cG250	DMJR6TC	Solid tumour/cancer	2A00-2F9Z	Phase 1	[49]
FERULIC ACID	DMJC7NF	Discovery agent	N.A.	Patented	[7]
PMID30074415-Compound-GS3	DM2G8DN	N. A.	N. A.	Patented	[42]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Aromatase (CYP19A1)	TTSZLWK	CP19A_HUMAN	Inhibitor	[2]
Carbonic anhydrase (CA)	TTUNARX	NOUNIPROTAC	Inhibitor	[3]
Carbonic anhydrase I (CA-I)	TTHQPL7	CAH1_HUMAN	Inhibitor	[3]
Carbonic anhydrase II (CA-II)	TTANPDJ	CAH2_HUMAN	Inhibitor	[3]
Carbonic anhydrase IV (CA-IV)	TTZHA0O	CAH4_HUMAN	Inhibitor	[3]
Carbonic anhydrase IX (CA-IX)	TT2LVK8	CAH9_HUMAN	Inhibitor	[3]
Carbonic anhydrase VI (CA-VI)	TTCFSPE	CAH6_HUMAN	Inhibitor	[3]
Carbonic anhydrase XII (CA-XII)	TTSYM0R	CAH12_HUMAN	Inhibitor	[3]
Carbonic anhydrase XIV (CA-XIV)	TTEYTKG	CAH14_HUMAN	Inhibitor	[3]
Steryl-sulfatase (STS)	TTHM0R1	STS_HUMAN	Inhibitor	[2]

References

• [1] Irosustat: a first-generation steroid sulfatase inhibitor in breast cancer. Expert Rev Anticancer Ther. 2011 Feb;11(2):179-83.
• [2] Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template. J Med Chem. 2010 Mar 11;53(5):2155-70.
• [3] Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6.
• [4] Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8.
• [5] Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
• [6] Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
• [7] Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
• [8] An Antibody-Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor Activities. Mol Cancer Ther. 2020 Aug;19(8):1660-1669.
• [9] Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
• [10] Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
• [11] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [12] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2597).
• [13] Understanding the Dual Inhibition of COX-2 and Carbonic Anhydrase-II by Celecoxib and CG100649 Using Density Functional Theory Calculations and other Molecular Modelling Approaches. Protein Pept Lett. 2015;22(10):903-12.
• [14] Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5435-9.
• [15] Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome. J Pediatr Endocrinol Metab. 2002;15 Suppl 3:945-8.
• [16] Aromatase inhibitors--theoretical concept and present experiences in the treatment of endometriosis. Zentralbl Gynakol. 2003 Jul-Aug;125(7-8):247-51.
• [17] Aminoglutethimide-induced protein free radical formation on myeloperoxidase: a potential mechanism of agranulocytosis. Chem Res Toxicol. 2007 Jul;20(7):1038-45.
• [18] Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach. J Med Chem. 2005 Nov 17;48(23):7282-9.
• [19] Aromatase inhibitors for male infertility. J Urol. 2002 Feb;167(2 Pt 1):624-9.
• [20] Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
• [21] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032111)
• [22] The taiwaniaquinoids: a review. J Nat Prod. 2010 Feb 26;73(2):284-98.
• [23] Sulfonamide linked neoglycoconjugates--a new class of inhibitors for cancer-associated carbonic anhydrases. J Med Chem. 2010 Apr 8;53(7):2913-26.
• [24] Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorg Med Chem. 2009 Jul 15;17(14):5054-8.
• [25] Localization of diuretic effects along the loop of Henle: an in vivo microperfusion study in rats. Clin Sci (Lond). 2000 Apr;98(4):481-8.
• [26] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [27] Selective effect of thiazides on the human osteoblast-like cell line MG-63. Kidney Int. 1996 Nov;50(5):1476-82.
• [28] Inhibition of carbonic anhydrases I and II by N-unsubstituted carbamate esters. J Biol Chem. 1992 Dec 15;267(35):25044-50.
• [29] Nature of the inhibition of carbonic anhydrase by acetazolamide and benzthiazide. J Pharmacol Exp Ther. 1961 Mar;131:271-4.
• [30] Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33.
• [31] Review of estrone sulfatase and its inhibitors--an important new target against hormone dependent breast cancer. Curr Med Chem. 2002 Jan;9(2):263-73.
• [32] 2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity. J Med Chem. 2006 Dec 28;49(26):7683-96.
• [33] Synergistic effects of E2MATE and norethindrone acetate on steroid sulfatase inhibition: a randomized phase I proof-of-principle clinical study in women of reproductive age. Reprod Sci. 2014 Oct;21(10):1256-65.
• [34] Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. Clin Cancer Res. 2006 Mar 1;12(5):1585-92.
• [35] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [36] Thiosemicarbazones of formyl benzoic acids as novel potent inhibitors of estrone sulfatase. J Med Chem. 2007 Jul 26;50(15):3661-6.
• [37] Estrogenic potential of 2-alkyl-4-(thio)chromenone 6-O-sulfamates: potent inhibitors of human steroid sulfatase. J Med Chem. 2003 Nov 6;46(23):5091-4.
• [38] Inhibition of estrone sulfatase (ES) by alkyl and cycloalkyl ester derivatives of 4-[(aminosulfonyl)oxy] benzoic acid. Bioorg Med Chem Lett. 2004 Feb 9;14(3):605-9.
• [39] Carbonic anhydrase inhibitors: Inhibition of the new membrane-associated isoform XV with phenols. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3593-6.
• [40] Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for th... Bioorg Med Chem Lett. 2008 Apr 15;18(8):2567-73.
• [41] Carbonic anhydrase inhibitors: crystallographic and solution binding studies for the interaction of a boron-containing aromatic sulfamide with mamm... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3601-5.
• [42] Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).Expert Opin Ther Pat. 2018 Oct;28(10):729-740.
• [43] Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1149-54.
• [44] Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with carboxylates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):573-8.
• [45] Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-assoc... Bioorg Med Chem Lett. 2004 Jan 5;14(1):217-23.
• [46] Potential role of (124)I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer. Biologics. 2012;6:395-407.
• [47] Carbonic anhydrase inhibitors. Inhibition of isozymes I, II, IV, V, and IX with anions isosteric and isoelectronic with sulfate, nitrate, and carbo... Bioorg Med Chem Lett. 2005 Feb 1;15(3):567-71.
• [48] Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9. Mol Cancer Ther. 2012 Feb;11(2):340-9.
• [49] Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma. Int J Mol Sci. 2013 May 29;14(6):11402-23.